Complete Response of severe idiopathic thrombocytopenic purpura after resection of bulky chromophobe renal cell carcinoma

2015 ◽  
Vol 22 (12) ◽  
pp. 1167-1169 ◽  
Author(s):  
Shigekatsu Maekawa ◽  
Masayoshi Nagata ◽  
Hiroshi Watanabe ◽  
Keina Nozaki ◽  
Atsuko Takahashi ◽  
...  

2020 ◽  
Vol 34 ◽  
pp. 205873842093161
Author(s):  
Xi Xie ◽  
Ning Wang ◽  
Jingjing Xiang ◽  
Huadong He ◽  
Xuliang Wang ◽  
...  

We presented the clinical data of one patient with renal cell carcinoma associated with idiopathic thrombocytopenic purpura in this case report. We reported a 56-year-old man who presented with petechiae and ecchymoses. Laboratory studies showed the platelet count of 2 × 109/L and an abdominal computed tomography (CT) scan revealed tumors in the right renal. There were purpura on the legs and cough without abdominal pain and melena at this time. Idiopathic thrombocytopenic purpura was diagnosed according to the clinical symptoms and laboratory test. The patient received radical nephrectomy for renal carcinoma, and his idiopathic thrombocytopenic purpura was cured after the surgery. Pathological biopsy confirmed it was renal clear cell carcinoma. The patient has been followed up for more than 3 months after surgery, and the ecchymoses had not been recurred and the patient’s thrombocytopenia was recovered. Idiopathic thrombocytopenic purpura associated with kidney cancer is rare. The patient in this case report was treated with radical nephrectomy, and the effectiveness of idiopathic thrombocytopenic purpura was satisfactory.


2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
An Uche ◽  
Chad Sila ◽  
Tad Tanoura ◽  
James Yeh ◽  
Neil Bhowmick ◽  
...  

Cabozantinib represents an established vascular endothelial growth factor- (VEGF-) tyrosine kinase inhibitor (TKI) in the treatment paradigm of metastatic renal cell carcinoma (mRCC). Its activity in mRCC patients with brain metastases (BMs) has been largely underreported in prospective clinical trials. We present the unique case of a heavily pretreated mRCC patient with BMs who achieved a brain complete response to cabozantinib prior to receiving radiation therapy. We end with a literature review and discussion of the biologic rationale and growing evidence supporting the intracranial activity of cabozantinib.


2007 ◽  
Vol 51 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Javier Salamanca ◽  
Nuria Alberti ◽  
Fernando López-Ríos ◽  
Andrés Perez-Barrios ◽  
Miguel Angel Martínez-González ◽  
...  

2021 ◽  
Vol 160 ◽  
pp. 103287 ◽  
Author(s):  
Rohan Garje ◽  
Dean Elhag ◽  
Hesham A Yasin ◽  
Luna Acharya ◽  
Daniel Vaena ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document